Sangamo Therapeutics Announces New Scientific Advisory Board
November 08 2019 - 8:30AM
Business Wire
Members include distinguished international
experts across a diverse range of scientific and therapeutic
areas
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, announced today that is has established a new Scientific
Advisory Board (SAB). The SAB comprises an eclectic group of
industry and academic experts who will advise Sangamo on its
current and future clinical programs and research and development
strategy.
“I am excited to be working with such a distinguished, diverse,
and imaginative group of experts who have joined our Scientific
Advisory Board to provide input into Sangamo’s research and
clinical development strategy, with a view to helping us identify
new opportunities for differentiation and innovation in the genomic
medicine space, and to define and address future trends,” said
Adrian Woolfson, B.M., B.Ch., Ph.D., Head of Research and
Development. “As Sangamo continues to advance programs from our
technology platforms into clinical programs, it is critical that we
obtain input from individuals with diverse expertise across a broad
range of relevant research and development areas."
The Sangamo SAB members are as follows:
- Roger Kornberg, Ph.D., Winzer Professor in Medicine, Structural
Biology Department, Stanford University Medical School (SAB
Chair)
- Dr. Mark Chee, Ph.D., President, Encodia, Inc., CEO and CSO,
Prognosys Biosciences
- Jef Boeke, Ph.D., D.Sc., Director, Institute for Systems
Genetics, NYU Langone Health
- Megan Levings, Ph.D., Professor, Department of Surgery and
School of Biomedical Engineering, University of British Columbia,
Lead, Childhood Diseases Theme, BC Children’s Hospital Research
Institute
- Stuart Schreiber, Ph.D., Morris Loeb Professor of Chemistry and
Chemical Biology, Harvard University
- Samuel Aparicio, B.M., B.Ch., Ph.D., FRCPath FRSC, Senior
Scientific Director of Cancer Genomics and Co-Chair, Enabling
Innovation Working Group, New York Genome Center
- Michael Grunstein, Ph.D., Distinguished Professor, Biological
Chemistry, UCLA- Department of Biological Chemistry
- Robert J. Desnick, Ph.D., M.D., D.Sc. (Hon)., Dean for Genetics
and Genomic Medicine & Professor & Chair Emeritus, Icahn
School of Medicine at Mount Sinai
- Douglas Higgs, FRS, Director, MRC Molecular Haematology Unit,
MRC Weatherall Institute of Molecular Medicine, University of
Oxford, John Radcliffe Hospital
- Frank Walsh, Ph.D., B.Sc., Founder and CEO, Ossianix
- Steven W. Pipe, M.D., Professor of Pediatrics and Pathology,
Laurence A. Boxer Research Professor of Pediatrics and Communicable
Diseases, Pediatric Medical Director, Hemophilia and Coagulation
Disorders Program, Director Special Coagulation Laboratory,
University of Michigan
- J Fraser Wright, Ph.D., Professor of Pediatrics, Center for
Definitive and Curative Medicine, Stanford University School of
Medicine, Principal, Wright Biologics Consulting.
For more information, please visit
https://www.sangamo.com/about-us/leadership.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic medicines with the potential
to transform patients' lives using gene therapy, ex vivo
gene-edited cell therapy, in vivo genome editing, and gene
regulation. For more information about Sangamo, visit
www.sangamo.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements regarding the Company's
ability to develop and commercialize product candidates to address
genetic diseases with the Company's proprietary technologies and
the timing of commencement or next stages of such programs and the
anticipated benefits therefrom. These statements are not guarantees
of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, the outcomes of clinical trials, the uncertain that
members of the SAB will remain engaged with Sangamo and the
uncertainties of the regulatory approval process. Actual results
may differ from those projected in forward-looking statements due
to risks and uncertainties that exist in Sangamo's operations and
business environments. These risks and uncertainties are described
more fully in Sangamo's Annual Report on Form 10-K for the year
ended December 31, 2018 as filed with the Securities and Exchange
Commission on March 1, 2019 and Sangamo's Quarterly Report on Form
10-Q for the quarter ended September 30, 2019 that it filed on
November 6, 2019. Forward-looking statements contained in this
announcement are made as of this date, and Sangamo undertakes no
duty to update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191108005095/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Media Inquiries – Global Aron
Feingold 510-970-6000, x421 afeingold@sangamo.com
Investor Relations and Media Inquiries –
European Union & United Kingdom Caroline Courme 33 4 97
21 27 27 ccourme@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024